ICMJE DISCLOSURE FORM

Date: <u>Nov. 30th, 2021</u> Your Name: <u>Silvio Matsas</u>	
Manuscript Title:Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: A systematic review and met	a-
Manuscript number (if known): JGO-23-808	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .	
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.	
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the follo	wing box:
	NOIIC.		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Nov 30th, 2023

Your Name: Pedro Nazareth Aguiar Junior

Manuscript Title: <u>Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: A systematic review and meta-analysis</u>

Manuscript number (if known): JGO-23-808

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Aché	Lecture Fee for me
		Amgen	Lecture Fee for me
		AstraZeneca	Lecture Fee for me
		Astellas	Lecture Fee for me
		Bayer	Lecture Fee for me
		Boehringer Ingelheim	Lecture Fee for me
		Gilead	Lecture Fee for me
		GSK	Lecture Fee for me
		Merck Co	Lecture Fee for me
		Sanofi	Lecture Fee for me
		Servier	Lecture Fee for me
		United Medical	Lecture Fee for me
6	Payment for expert	XNone	
	testimony		
7	Support for attending	AstraZeneca	Accomodation and Registration for me at ISPOR Europe
	meetings and/or travel		2023
8	Patents planned, issued or	X None	
	pending	XNone	
	Periamg		
_			
9 Participation on a Data		Adium	Advisory Board Fee
	Safety Monitoring Board or	Gilead	Advisory Board Fee
	Advisory Board	Daiichi Sankyo	Advisory Board Fee
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	indicial interests		

Please summarize the above conflict of interest in the following box:

I received lecture honoraria from Aché, Amgen, AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Gilead, GSK, Merck Co, Sanofi, Servier and United Medical. I received Advisory Board Fee from Adium, Gilead and Daiichi Sankyo. I received support for attending a meeting from AstraZeneca. None of them are related to this manuscript.

Please place an "X" next to the following statement to indicate your agreement:					
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

ICMJE DISCLOSURE FORM

Date: <u>11/28/23</u>	
Your Name: Auro del Giglio	
Manuscript Title: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to	
prognosticate survival in advanced gastric cancer patients in the era of	
immunotherapy: A systematic review and meta-analysis"	
Manuscript number (if known): Manuscript JGO-23-808	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	

4	Consulting fees	x None	
	consuming rees		
5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
	5 ,		
8	Patents planned, issued or	x None	
- 0	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	_xNone	
12	Receipt of equipment,	x None	
12	materials, drugs, medical	_xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests		
88 			

Please summarize the above conflict of interest in the following box:

No conflicts of interest			

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.